HC Wainwright Brokers Boost Earnings Estimates for Krystal Biotech, Inc. (NASDAQ:KRYS)

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities research analysts at HC Wainwright raised their Q2 2024 earnings per share estimates for Krystal Biotech in a research report issued on Monday, May 6th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn $0.37 per share for the quarter, up from their prior forecast of $0.10. HC Wainwright currently has a “Buy” rating and a $200.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $1.82 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q3 2024 earnings at $0.31 EPS, Q4 2024 earnings at $0.18 EPS and FY2024 earnings at $0.89 EPS.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.17). The business had revenue of $45.25 million for the quarter, compared to analyst estimates of $47.37 million. During the same quarter in the prior year, the company earned ($1.76) EPS. The business’s revenue for the quarter was up 452400.0% on a year-over-year basis.

A number of other equities research analysts also recently commented on the stock. Guggenheim lifted their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Citigroup lifted their price objective on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. William Blair reissued an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Finally, Stifel Nicolaus restated a “buy” rating and set a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of “Buy” and an average price target of $171.00.

Krystal Biotech Stock Down 2.5 %

KRYS opened at $157.68 on Wednesday. Krystal Biotech has a twelve month low of $86.03 and a twelve month high of $189.97. The firm has a 50 day moving average price of $168.76 and a 200-day moving average price of $134.27. The stock has a market capitalization of $4.50 billion, a price-to-earnings ratio of 1,971.25 and a beta of 0.91.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. grew its stake in shares of Krystal Biotech by 111.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock valued at $83,000 after buying an additional 379 shares during the last quarter. Quest Partners LLC purchased a new stake in Krystal Biotech during the fourth quarter valued at approximately $127,000. Pier 88 Investment Partners LLC acquired a new stake in shares of Krystal Biotech in the 4th quarter worth $145,000. Headlands Technologies LLC purchased a new stake in shares of Krystal Biotech during the first quarter worth about $291,000. Finally, Fox Run Management L.L.C. purchased a new stake in Krystal Biotech during the 3rd quarter worth approximately $219,000. Institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the transaction, the insider now directly owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 8,087 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $136.91, for a total transaction of $1,107,191.17. Following the completion of the transaction, the chief accounting officer now directly owns 12,556 shares in the company, valued at approximately $1,719,041.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,087 shares of company stock valued at $6,210,591. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).